125 related articles for article (PubMed ID: 34763305)
1. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
3. Apomorphine Sublingual Film Compared with Subcutaneous Apomorphine for OFF Episodes in Parkinson's Disease: An Open-Label, Randomized, Crossover Study.
Stocchi F; Rascol O; Poewe W; Chaudhuri KR; Kassubek J; Lopez Manzanares L; Zhang Y; Bowling A; Pappert E; Wu S;
J Parkinsons Dis; 2023; 13(8):1329-1342. PubMed ID: 37980683
[TBL] [Abstract][Full Text] [Related]
4. Sublingual apomorphine in treatment of Parkinson's disease: a review.
Hislop J; Margolesky J; Shpiner DS
Int J Neurosci; 2024 May; 134(5):474-480. PubMed ID: 35986574
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
Thijssen E; Tuk B; Cakici M; van Velze V; Klaassen E; Merkus F; van Laar T; Kremer P; Groeneveld GJ
Clin Transl Sci; 2024 May; 17(5):e13796. PubMed ID: 38712716
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study.
Kassubek J; Stocchi F; Martinez EB; Pahwa R; Ondo W; Zhang Y; Bowling A; Pappert E; Isaacson S; Wu S;
Ther Adv Neurol Disord; 2023; 16():17562864231209240. PubMed ID: 37954918
[TBL] [Abstract][Full Text] [Related]
7. Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38578533
[TBL] [Abstract][Full Text] [Related]
8. Terminal Care in Parkinson's Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort.
Béreau M; Giffard M; Clairet AL; Degenne G; Tatu L; Richfield E; Magnin E; Vérin M; Auffret M
J Parkinsons Dis; 2024; 14(1):209-219. PubMed ID: 38217611
[TBL] [Abstract][Full Text] [Related]
9. Intermittent Apomorphine Use for off Period Rescue in Parkinson's Disease: A Pragmatic Review of over Three Decades of Clinical Experience.
Castillo-Torres SA; Lees AJ; Merello M
Mov Disord Clin Pract; 2023 Feb; 10(2):190-208. PubMed ID: 36825043
[TBL] [Abstract][Full Text] [Related]
10. Sublingual apomorphine in the treatment of Parkinson's disease.
Kassubek J; Jost WH; Schwarz J
J Neural Transm (Vienna); 2024 May; ():. PubMed ID: 38743091
[TBL] [Abstract][Full Text] [Related]
11. High-dose thiamine as initial treatment for Parkinson's disease.
Costantini A; Pala MI; Compagnoni L; Colangeli M
BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23986125
[TBL] [Abstract][Full Text] [Related]
12. Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson's disease.
Nasser A; Gomeni R; Ceresoli-Borroni G; Xie L; Busse GD; Melyan Z; Rubin J
J Pharmacokinet Pharmacodyn; 2024 May; ():. PubMed ID: 38816542
[No Abstract] [Full Text] [Related]
13. Apomorphine at the End-of-Life-A Role to Play.
Azoia C; Borges C; Velon AG; Raimundo R
Mov Disord Clin Pract; 2023 Dec; 10(12):1827-1829. PubMed ID: 38094651
[No Abstract] [Full Text] [Related]
14. Comparative Efficacy and Safety of Dopamine Agonists in Advanced Parkinson's Disease With Motor Fluctuations: A Systematic Review and Network Meta-Analysis of Double-Blind Randomized Controlled Trials.
Ruan X; Lin F; Wu D; Chen L; Weng H; Yu J; Wang Y; Chen Y; Chen X; Ye Q; Meng F; Cai G
Front Neurosci; 2021; 15():728083. PubMed ID: 34776841
[No Abstract] [Full Text] [Related]
15. Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Pringsheim T; Day GS; Smith DB; Rae-Grant A; Licking N; Armstrong MJ; de Bie RMA; Roze E; Miyasaki JM; Hauser RA; Espay AJ; Martello JP; Gurwell JA; Billinghurst L; Sullivan K; Fitts MS; Cothros N; Hall DA; Rafferty M; Hagerbrant L; Hastings T; O'Brien MD; Silsbee H; Gronseth G; Lang AE;
Neurology; 2021 Nov; 97(20):942-957. PubMed ID: 34782410
[TBL] [Abstract][Full Text] [Related]
16. Anticholinergic Medication Burden in Parkinson's Disease Outpatients.
Nawaz H; Sargent L; Quilon H; Cloud LJ; Testa CM; Snider JD; Lageman SK; Baron MS; Berman BD; Zimmerman K; Price ET; Mukhopadhyay ND; Barrett MJ
J Parkinsons Dis; 2022; 12(2):599-606. PubMed ID: 34806617
[TBL] [Abstract][Full Text] [Related]
17. The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A
Rocha JF; Ebersbach G; Lees A; Tolosa E; Ferreira JJ; Poewe W; Rascol O; Stocchi F; Antonini A; Magalhães D; Gama H; Soares-da-Silva P
Front Neurol; 2021; 12():754016. PubMed ID: 34803891
[No Abstract] [Full Text] [Related]
18. Role of Cleaved PINK1 in Neuronal Development, Synaptogenesis, and Plasticity: Implications for Parkinson's Disease.
Soman SK; Dagda RK
Front Neurosci; 2021; 15():769331. PubMed ID: 34795558
[TBL] [Abstract][Full Text] [Related]
19. Temporal dynamics of cortical activity and postural control in response to the first levodopa dose of the day in people with Parkinson's disease.
Araújo-Silva F; Santinelli FB; Felipe I Imaizumi L; Silveira APB; Vieira LHP; Alcock L; Barbieri FA
Brain Res; 2022 Jan; 1775():147727. PubMed ID: 34788638
[TBL] [Abstract][Full Text] [Related]
20. Parkinson's disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients.
Toyoshima Y; Takahashi H; Katada S; Kojima N; Tada M; Tani T; Koike R; Nozawa T; Aida I; Nakajima T; Onodera O; Kakita A
Neuropathology; 2021 Dec; 41(6):450-456. PubMed ID: 34779072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
